Insights

Milestone GSK collaboration CureVac recently received a €400 million upfront payment from a restructured collaboration with GSK, reflecting a strengthened financial position. This infusion could signal potential areas for new collaborations or partnerships with other pharmaceutical companies looking to leverage CureVac's mRNA technology.

Positive Phase 2 data CureVac's successful Phase 2 data from its seasonal influenza program, licensed to GSK, may present an opportunity for further discussions with GSK or other companies looking to expand their vaccine portfolios. This achievement showcases the effectiveness of CureVac's technology and could attract interest from potential buyers or collaborators.

New cancer vaccine program With the development of off-the-shelf and personalized cancer vaccine product candidates utilizing mRNA technology, CureVac is venturing into a promising therapeutic area. This innovation could spark interest from investors or companies seeking to diversify into the oncology space, presenting a potential avenue for business development partnerships or investments.

Strategic workforce reduction CureVac's corporate redesign, including a 30% reduction in their workforce, is expected to yield significant cost savings and operational agility. This streamlining could offer opportunities for cost-effective collaborations or acquisitions for companies looking to leverage CureVac's expertise and potentially acquire talent affected by the restructuring.

Recognized as global innovator Being consistently recognized as one of the world's top innovators by reputable organizations like LexisNexis positions CureVac as a key player in the biopharmaceutical industry. This recognition could attract potential partnerships or investments from companies seeking to align with innovative leaders in the mRNA technology space.

CureVac Tech Stack

CureVac uses 8 technology products and services including Google Analytics, SAP SuccessFactors, SAP, and more. Explore CureVac's tech stack below.

  • Google Analytics
    Analytics
  • SAP SuccessFactors
    Applicant Tracking Systems
  • SAP
    Customer Relationship Management
  • SAP HANA
    Database Management
  • SAP S/4HANA
    Enterprise Resource Planning
  • Google Font API
    Font Scripts
  • IBM
    Miscellaneous
  • SAP Ariba
    Procurement

Media & News

CureVac's Email Address Formats

CureVac uses at least 1 format(s):
CureVac Email FormatsExamplePercentage
First.Last@curevac.comJohn.Doe@curevac.com
97%
First.MiddleLast@curevac.comJohn.MichaelDoe@curevac.com
2%
LF@curevac.comDJ@curevac.com
1%

Frequently Asked Questions

Where is CureVac's headquarters located?

Minus sign iconPlus sign icon
CureVac's main headquarters is located at Friedrich-Miescher-Str. 15 Tübingen, Baden-Württemberg 72076 DE. The company has employees across 5 continents, including EuropeNorth AmericaSouth America.

What is CureVac's phone number?

Minus sign iconPlus sign icon
You can contact CureVac's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CureVac's stock symbol?

Minus sign iconPlus sign icon
CureVac is a publicly traded company; the company's stock symbol is CVAC.

What is CureVac's official website and social media links?

Minus sign iconPlus sign icon
CureVac's official website is curevac.com and has social profiles on LinkedIn.

How much revenue does CureVac generate?

Minus sign iconPlus sign icon
As of January 2025, CureVac's annual revenue reached $750M.

What is CureVac's SIC code NAICS code?

Minus sign iconPlus sign icon
CureVac's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CureVac have currently?

Minus sign iconPlus sign icon
As of January 2025, CureVac has approximately 1K employees across 5 continents, including EuropeNorth AmericaSouth America. Key team members include Chief Executive Officer: A. Z.Chief Business Officer: T. R.Chief Operating Officer: M. G.. Explore CureVac's employee directory with LeadIQ.

What industry does CureVac belong to?

Minus sign iconPlus sign icon
CureVac operates in the Biotechnology Research industry.

What technology does CureVac use?

Minus sign iconPlus sign icon
CureVac's tech stack includes Google AnalyticsSAP SuccessFactorsSAPSAP HANASAP S/4HANAGoogle Font APIIBMSAP Ariba.

What is CureVac's email format?

Minus sign iconPlus sign icon
CureVac's email format typically follows the pattern of . Find more CureVac email formats with LeadIQ.

How much funding has CureVac raised to date?

Minus sign iconPlus sign icon
As of January 2025, CureVac has raised $250M in funding. The last funding round occurred on Feb 07, 2023 for $250M.

When was CureVac founded?

Minus sign iconPlus sign icon
CureVac was founded in 2000.
CureVac

CureVac

Biotechnology ResearchBaden-Württemberg, Germany1001-5000 Employees

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

Section iconCompany Overview

Headquarters
Friedrich-Miescher-Str. 15 Tübingen, Baden-Württemberg 72076 DE
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CVAC
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2000
Employees
1001-5000

Section iconFunding & Financials

  • $250M

    CureVac has raised a total of $250M of funding over 14 rounds. Their latest funding round was raised on Feb 07, 2023 in the amount of $250M.

  • $100M$1B

    CureVac's revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $250M

    CureVac has raised a total of $250M of funding over 14 rounds. Their latest funding round was raised on Feb 07, 2023 in the amount of $250M.

  • $100M$1B

    CureVac's revenue is in the range of $100M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.